drugset / Trial / NCT01324518

Safety and Efficacy of ORM-12741 in Patients With Alzheimer's Disease

NCT01324518 ↗

Phase 2 Completed 100 enrolled Orion Corporation, Orion Pharma
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether ORM-12741 is safe and effective in the treatment of Alzheimer's disease.

Timeline

Start
2011-04
Primary completion
2012-09
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject ORM-12741 Small molecule 60 mg —
Subject ORM-12741 Small molecule 200 mg —

Indications